AC
CRL icon

Ascend Capital’s Charles River Laboratories CRL Stock Holding History

Ascend Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-157,465
Closed -$9.5M – 182
2014
Q1 		$9.5M Buy
+157,465
New +$9.18M 0.25% 108

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ascend Capital's CRL Position: Q2 2014 in Review

Ascend Capital sold out of Charles River Laboratories (CRL) in Q2 2014, closing a stake of 157,465 shares — an estimated $9.5M sold.

Ascend Capital first reported a position in CRL in Q1 2014 and held it in 1 quarter. The position peaked at $9.5M in Q1 2014. 262 funds tracked by Wall St. Rank hold CRL as of Q2 2014.

  • Ascend Capital reported no remaining Charles River Laboratories position as of Q2 2014 after selling out during the quarter.
  • Ascend Capital sold 157,465 Charles River Laboratories shares in Q2 2014, an estimated $9.5M.
  • Ascend Capital first reported a position in Charles River Laboratories in Q1 2014 and held it in 1 quarter.
  • Ascend Capital's Charles River Laboratories position peaked at $9.5M in Q1 2014.
  • 262 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2014.

Based on Ascend Capital's 13F filing for Q2 2014, filed 13 Aug 2014.